Related Experiment Video

Updated: Aug 17, 2026

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib
09:38

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Published on: June 26, 2019

Epidermal growth factor receptor inhibitors and their role in non-small-cell lung cancer

Brian J Byrne1, Jennifer Garst

  • 1Duke University Medical Center, Durham, NC 27710, USA. byrne005@mc.duke.edu

Current Oncology Reports
|June 11, 2005
PubMed

Insights

Epidermal growth factor receptor (EGFR) targeted therapies show promise for advanced non-small-cell lung cancer (NSCLC). Patient characteristics like female sex, non-smoker status, Asian race, and specific EGFR mutations predict treatment response.

Area of Science:

  • Oncology
  • Pharmacogenomics
  • Medical Genetics

Background:

  • Epidermal growth factor receptor (EGFR) is a key target in advanced non-small-cell lung cancer (NSCLC) treatment.
  • Erlotinib and gefitinib are FDA-approved EGFR inhibitors for NSCLC; cetuximab is under investigation.
  • Erlotinib has demonstrated a survival benefit in advanced NSCLC patients.

Purpose of the Study:

  • To review the role of EGFR in NSCLC treatment.
  • To identify patient populations and genetic factors associated with improved response to EGFR inhibitors.

Main Methods:

  • Literature review of clinical trials and genetic studies on EGFR inhibitors in NSCLC.
  • Analysis of patient demographics and clinical characteristics associated with treatment outcomes.
  • Correlation of EGFR mutations with response rates to targeted therapies.

Main Results:

  • Erlotinib has shown improved survival in advanced NSCLC.
  • Predictive factors for response include female sex, non-smoker status, Asian race, good performance status, and adenocarcinoma histology.
  • Specific EGFR mutations are strongly correlated with increased patient response to EGFR-targeted drugs.

Conclusions:

  • EGFR inhibitors represent a significant advancement in NSCLC therapy.
  • Identifying patients with favorable predictive markers, including specific EGFR mutations, can optimize treatment selection and improve outcomes.

More Related Videos

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure09:38

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Published on: August 11, 2017

Related Concept Videos

Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Enzyme-linked Receptors01:00

Enzyme-linked Receptors

Enzyme-linked receptors are proteins that act as both receptor and enzyme, activating multiple intracellular signals. This is a large group of receptors that include the receptor tyrosine kinase (RTK) family. Many growth factors and hormones bind to and activate the RTKs.
Neurotrophin (NT) receptors are a family of RTKs, including trkA, trkB, and trkC (tropomyosin-related kinase) receptors. TrkA is specific for nerve growth factor (NGF), neurotrophin-6, and neurotrophin-7. TrkB binds...
Small GTPases - Ras and Rho01:24

Small GTPases - Ras and Rho

Ras and Rho are small monomeric GTPases that act downstream of receptor tyrosine kinase (RTK) and regulate various cellular processes. These GTPases switch between active and inactive states by binding to guanine nucleotides.
Three regulatory proteins control their activity: